- February 25, 2025
- Marc Suárez-Calvet, et al., BarcelonaBeta BRC
Topic/Product:
CNS Disease Panel 120
Disease Area:
Alzheimer's Disease
Sample Type:
Plasma
Abstract
INTRODUCTION
Blood‐based biomarkers for Alzheimer’s disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited.
METHODS
In this cross‐sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p‐tau181, p‐tau217, p‐tau231, t‐tau, and Aβ42/40 to classify Aβ pathology status.
RESULTS
Plasma p‐tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t‐tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p‐tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p‐tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers.
DISCUSSION
Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting.
Highlights
Plasma p‐tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t‐tau and Aβ42/40 assays in detecting Alzheimer’s disease.
Among the p‐tau biomarkers, p‐tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites.
p‐tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers.
Several plasma p‐tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer’s disease.
Authors & Affiliations
Federica Anastasi¹²³, Aida Fernández-Lebrero¹²⁴⁵, Nicholas J. Ashton⁶⁷⁸⁹, Paula Ortiz-Romero¹², Javier Torres-Torronteras¹², Armand González-Escalante¹²⁵, Marta Milà-Alom๹⁰, José Contador¹²⁴, Greta García-Escobar²⁴, Rosa María Manero-Borràs⁴, Irene Navalpotro-Gómez¹²⁴⁵, Esther Jiménez-Moyano¹², Aparna Sahajan¹¹, Qinyu Hao¹¹, Bingqing Zhang¹¹, Andreas Jeromin¹², Nathalie Le Bastard¹³, Alicia Nadal¹⁴, Tahmine Mousavi¹⁵, Gwendlyn Kollmorgen¹⁶, Margherita Carboni¹⁷, Oriol Grau-Rivera¹²⁴¹⁸, Henrik Zetterberg⁶¹⁹²⁰²¹²²²³, Marta del Campo¹²²⁴, Kaj Blennow⁶¹⁹²⁵, Albert Puig-Pijoan¹²⁴²⁶, and Marc Suárez-Calvet¹²⁴
¹ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
² Hospital del Mar Research Institute, Barcelona, Spain
³ Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
⁴ Servei de Neurologia, Hospital del Mar, Barcelona, Spain
⁵ Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
⁶ Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
⁷ King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK
⁸ Banner Alzheimer’s Institute, Phoenix, AZ, USA
⁹ Banner Sun Health Research Institute, Sun City, AZ, USA
¹⁰ Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
¹¹ Alamar Biosciences, Inc., Fremont, CA, USA
¹² ALZpath, Carlsbad, CA, USA
¹³ Fujirebio Europe N.V., Gent, Belgium
¹⁴ Fujirebio Iberia, Barcelona, Spain
¹⁵ Meso Scale Diagnostics, LLC., Rockville, MD, USA
¹⁶ Roche Diagnostics GmbH, Penzberg, Germany
¹⁷ Roche Diagnostics International Ltd, Rotkreuz, Switzerland
¹⁸ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain
¹⁹ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
²⁰ Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
²¹ UK Dementia Research Institute at UCL, London, UK
²² Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
²³ Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI, USA
²⁴ Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
²⁵ Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
²⁶ Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain